http://www.mdvu.org/emove Articles from E-Move en-us http://www.mdvu.org/emove/article.asp?ID=1288 WE MOVE announces the launch of its latest educational activity designed to illustrate the factors that impede timely and accurate diagnosis. The Clin http://www.mdvu.org/emove/article.asp?ID=1286 The American Academy of Neurology has formulated a set of 10 quality measures for care of Parkinson’s disease patients. The measures are designed http://www.mdvu.org/emove/article.asp?ID=1285 REM sleep behavior disorder (RBD) may precede Parkinson’s disease or other forms of alpha-synucleinopathy by up to 50 years, according to a new st http://www.mdvu.org/emove/article.asp?ID=1284 WE MOVE is pleased to announce the launch of a new continuing medical education activity: Pediatric Movement Disorders: Diagnosis, Assessment a http://www.mdvu.org/emove/article.asp?ID=1283 Dopamine agonist stimulation reduces activity in brain networks linked to impulse control and response inhibition, according to a new study. In PD http://www.mdvu.org/emove/article.asp?ID=1282 The protein encoded by DYT6 links to the promoter of the DYT1 gene, according to a new study. The two genes are the only genes identified as causes of http://www.mdvu.org/emove/article.asp?ID=1278 Amantadine reduces pathological gambling in Parkinson’s disease patients taking dopamine agonists, according to a new study. Seventeen PD patie http://www.mdvu.org/emove/article.asp?ID=1277 The degree of dopamine release induced by placebo varies with the patient’s expectation of receiving active medication, according to a new study, http://www.mdvu.org/emove/article.asp?ID=1276 A variant in a human leukocyte antigen (HLA) gene is associated with increased risk for Parkinson’s disease, according to a new study. The HLA gene http://www.mdvu.org/emove/article.asp?ID=1274 The United States Food and Drug Administration has approved Xeomin (incobotulinumtoxinA) for treatment of cervical dystonia and blepharospasm. Xeo